The STRIVE trial shows intracoronary low-dose alteplase doesn’t improve outcomes in #STEMI with large thrombus and may raise arrhythmic risk—closing the door on this adjunctive fibrinolysis strategy during primary #PCI. https://t.co/WiTnjiyr9q
#TCT2025#JACC#MACE@DrNataliaP
We all know that it's not just mortality though, need to also think about re-infarction and rpt revasc. The most interesting slide was the one of PCI with and without imaging vs cabg
Game-changing balloon-expandable #TAVR platform MiRus® #Siegel valve 30d EFS presented #TCT2025 by @PradeepYadavMD !
- Rhenium frame nickel free, porcine dry pack tissue with anticalcification
- 8F expandable sheath
- Short height but high radial strength
- PVL skirt
- Commissural alignment flags
- Single-digit gradients with EOA >2.0 in 23 mm and ~2.5 in 26 mm TAV
- 0 complications @ 30d, 2/30 had pacemaker (no pacing needed)
Pivotal all-comers RCT coming soon!
Proud to be part of this journey @MountSinaiHeart@MountSinaiNYC@IcahnMountSinai@KHERA_MD@DLBHATTMD@LucySafi@DoctorKini #SaminSharmaMD
#TCT2025@TCTConference@crfheart 10 year results of Noble Trial
🧨PCI vs. CABG: similar all-cause mortality
🧨No difference at 0-5 and 5-10 years
🧨In ACS: PCI associated with lower mortality
🧨SYNTAX score: no association with mortality
2nd study this week suggesting PCI imaging guidance may eliminate diffs vs CABG in MVD, this one from BEST trial publ in HEART. 12yr-MACE after CABG 24.0% vs angio-PCI 44.3% (adjHR 2.23; p<0.001), vs IVI-PCI 22.8% (adjHR 1.01; p=0.93). Our free editorial: https://t.co/nJh06Fub2P
Meet the Course Directors behind PCI Course London 2025.
From October 8–10, this expert-led programme will be shaped by the insights and experience of leading interventional cardiologists:
@jcspratt, Margaret McEntegart, Colm Hanratty, @SibbaldMatt & @ColletCarlos
Get ready for three days of cutting-edge education, practical insight, and collaborative learning.
🔗https://t.co/whjCg9QVx1 #OptimaPCILondon25
Last May 1st we were very excited presenting two simultaneous live cases from Mexico City for
#SCAI2025#SCAI
1) Heterotopic Transcatheter Tricuspid Valve Replacement (TricValve)
2) Embolization of Pulmonary arteriovenous malformation
What an honor. @scai
Curso de Intervencionismo Cardiovascular
CIC 2025.
Gran oportunidad de compartir experiencias en el ambito de la Intervención cardiaca coronaria y estructural, excelentes casos en vivo.
Los invitamos.
3 y 4 de abril
#CIC2025
We launched a new academic collaboration between @MayoClinicCV and Instituto Nacional de Cardiología Ignacio Chávez @Cardiologia_MX@jorgegasparh in México City as well as the Hermosillo Heart Team @TeamHermosillo at CIMA Hospital @CIMAHMO in Hermosillo, Sonora, Mexico. Our 1st. Academic event was a SHD Interventions Symposium with speakers from both institutions and a wonderful Keynote Lecture by @drpaulfriedman on “Artificial Intelligence in Cardiology: Where are we? And where are we going?” I trust this is only the beginning of a long-lasting and very productive academic collaboration. Thank you all!!! With deepest gratitude! 🙏 ❤️🙏
We launched a new academic collaboration between @MayoClinicCV and the National Institute of Cardiology @Cardiologia_Mx in Mexico City and CIMA Hospital @CIMAHMO in Hermosillo Sonora Mexico where the first transseptal direct mitral annuloplasty case with Silara MiBridge device in North America was done few days ago. Excellent results! Eternally grateful for this new academic collaboration 🙏❤️